Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2021-08-30 Share Issue/Capital Cha…
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - PTX 6 pages 27.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, prices, and the resulting issued capital. This is a regulatory announcement related to capital changes but does not constitute a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the securities issued. The document fits best under the category of Share Issue/Capital Change (SHA), as it announces new securities being quoted following option exercises and conversions.
2021-08-30 English
Appendix 4E and 2021 Annual Report 50 pages 1.4MB
Annual Report Classification · 100% confidence The document is titled 'Prescient Therapeutics Limited Appendix 4E Preliminary final report' and includes detailed financial results for the year ended 30 June 2021, including revenues, losses, net assets, and dividends. It also contains a Chair's Letter, Directors' report, financial statements, auditor's report, and other comprehensive financial information. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of detailed financial statements and management commentary confirms this is a full annual report. The mention of 'Annual Report' and the detailed contents list further support this classification. Therefore, the document is best classified as an Annual Report (10-K equivalent). FY 2021
2021-08-29 English
Appendix 4G and Corporate Governance Statement 25 pages 663.6KB
Governance Information Classification · 100% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a governance-related disclosure document for Prescient Therapeutics Limited for the financial year ended 30 June 2021. The content includes detailed tables showing compliance with corporate governance recommendations, locations of disclosures, and explanations for non-compliance. It is not a full annual report, audit report, or financial statement, but rather a governance disclosure document required by the ASX listing rules. The document is not an announcement of a report but a substantive governance disclosure. Therefore, it fits the category of Governance Information (CGR).
2021-08-29 English
Global brain cancer expert joins PTX advisory board 4 pages 298.7KB
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Professor Donald M. O’Rourke, MD, to the Scientific Advisory Board of Prescient Therapeutics. It focuses on the expertise of the new board member and the company's ongoing research programs, including CAR-T therapies and targeted therapies. There is no financial data, no regulatory filing references, no voting results, no earnings information, and no detailed report content. The document is an announcement related to board/management information, specifically the addition of a senior scientific advisor to the company's advisory board. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is sufficient and contains substantive content about the appointment, not just a brief notice or report publication announcement.
2021-08-18 English
Investor Presentation 21 pages 1.9MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and includes detailed company updates, product pipeline information, corporate snapshot, and strategic plans. It mentions a CEO presentation at an investor briefing and provides extensive information about the company's therapies and financial metrics. The length is substantial (15,000 characters), and the content is consistent with a presentation aimed at investors, focusing on financials, strategy, and market position. There is no indication that this is a regulatory filing, earnings release, or annual report. Therefore, the document fits the definition of an Investor Presentation (IP).
2021-08-03 English
June 2021 Quarterly Activities and Appendix 4C 10 pages 404.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'June 2021 Activities Report and Appendix 4C' and contains detailed quarterly operational and financial updates, including cash flow information, clinical progress, collaborations, and financial position. It references the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules. The content includes substantive financial data and analysis for the quarter ended 30 June 2021, such as cash balances, expenditures, and clinical trial progress. This matches the characteristics of an Interim / Quarterly Report (IR), which provides comprehensive financial and operational information for a period shorter than a full fiscal year. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2021
2021-07-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.